Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 11Burkitt Lymphoma 8Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Smoldering Multiple Myeloma 2Lymphoma, Mantle-Cell 2Immunoglobulin Light-chain Amyloidosis 2Down Syndrome 2Neoplasm Metastasis 1Lung Neoplasms 1Leukemia, Plasma Cell 1Leukemia, Biphenotypic, Acute 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Ann Arbor Stage II Mantle Cell Lymphoma 1

Interventions

dexamethasone acetate 2dexamethasone 21-phosphate 2auricularum 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Dexamethasone 2Calcium Dobesilate 2Biopsy 24-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene 2venetoclax 1ixazomib 1daratumumab 1belantamab mafodotin 1X-Rays 1Stem Cell Transplantation 1Phantoms, Imaging 1Melphalan 1Cyclophosphamide 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Immunoglobulin Light-chain Amyloidosis × dexamethasone 21-phosphate × 30 days × Clear all
NCT04847453 2026-05-13

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

National Cancer Institute (NCI)

Phase 1 Active not recruiting
24 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT06022939 2026-05-06

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

SWOG Cancer Research Network

Phase 3 Recruiting
338 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡